{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:22:34Z","timestamp":1769502154798,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471180"],"award-info":[{"award-number":["81471180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671132"],"award-info":[{"award-number":["81671132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701142"],"award-info":[{"award-number":["81701142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The use of antiplatelet agents in ischemic moyamoya disease (MMD) is controversial. This study aimed to investigate the effectiveness and safety of antiplatelet therapy compared with conservative treatment and surgical revascularization in ischemic MMD patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Ischemic MMD patients were retrospectively enrolled from eight clinical sites from January 2013 to December 2018. Follow-up was performed through clinical visits and\/or telephone interviews from first discharge to December 2019. The primary outcome was the episodes of further ischemic attacks, and the secondary outcome was the individual functional status. Risk factors for future stroke were identified by the LASSO-Cox regression model. Propensity score matching was applied to assemble a cohort of patients with similar baseline characteristics using the <jats:italic>TriMatch<\/jats:italic> package.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among 217 eligible patients, 159 patients were included in the analyses after a 1:1:1 propensity score matching. At a mean follow-up of 33 months, 12 patients (7.5%) developed further incident cerebral ischemic events (surgical:antiplatelet:conservative = 1:3:8; <jats:italic>p<\/jats:italic> = 0.030), 26 patients (16.4%) developed a poor functional status (surgical:antiplatelet:conservative = 7:12:7; <jats:italic>p<\/jats:italic> = 0.317), and 3 patients (1.8%) died of cerebral hemorrhage (surgical:antiplatelet:conservative = 1:2:0; <jats:italic>p<\/jats:italic> = 0.361). The survival curve showed that the risk of further cerebral ischemic attacks was lowest with surgical revascularization, while antiplatelet therapy was statistically significant for preventing recurrent risks compared with conservative treatment (\u03c7<jats:sup>2<\/jats:sup> = 8.987; <jats:italic>p<\/jats:italic> = 0.011). No significant difference was found in the functional status and bleeding events. The LASSO-Cox regression model revealed that a family history of MMD (HR = 6.93; 95% CI: 1.28\u201337.52; <jats:italic>p<\/jats:italic> = 0.025), a past history of stroke or transient ischemic attack (HR = 4.35; 95% CI: 1.09\u201317.33; <jats:italic>p<\/jats:italic> = 0.037), and treatment (HR = 0.05; 95% CI: 0.01\u20130.32; <jats:italic>p<\/jats:italic> = 0.001) were significantly related to the risk of recurrent strokes.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Antiplatelet agents were effective and safe in preventing further cerebral ischemic attacks in adult patients with ischemic MMD. They may be a replacement therapy for patients with surgical contraindications and for patients prior to revascularization.<\/jats:p>","DOI":"10.3389\/fneur.2020.608000","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T05:52:20Z","timestamp":1610689940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Fei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianzhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMra0804622","article-title":"Moyamoya disease and moyamoya syndrome","volume":"360","author":"Scott","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1136\/jnnp.2007.130666","article-title":"Novel epidemiological features of moyamoya disease","volume":"79","author":"Baba","year":"2008","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1161\/01.STR.29.7.1347","article-title":"Clinical features of moyamoya disease in the United States","volume":"29","author":"Chiu","year":"1998","journal-title":"Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1161\/STROKEAHA.107.513408","article-title":"Moyamoya disease in Europeans","volume":"39","author":"Kraemer","year":"2008","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/STROKEAHA.107.490714","article-title":"Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey","volume":"39","author":"Kuriyama","year":"2008","journal-title":"Stroke"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1161\/STROKEAHA.111.621300","article-title":"Moyamoya disease in China: its clinical features and outcomes","volume":"43","author":"Duan","year":"2012","journal-title":"Stroke"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1161\/STROKEAHA.113.004273","article-title":"Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study","volume":"45","author":"Ahn","year":"2014","journal-title":"Stroke"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/STROKEAHA.113.004160","article-title":"Epidemiology of moyamoya disease in Taiwan: a nationwide population-based study","volume":"45","author":"Chen","year":"2014","journal-title":"Stroke"},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2176\/nmc.52.245","article-title":"Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","journal-title":"Neurol Med Chir."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"B12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1331.2011.03481.x","article-title":"What is the expert's option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey","volume":"19","author":"Kraemer","year":"2012","journal-title":"Euro J Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.003","article-title":"Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in Japan","volume":"25","author":"Yamada","year":"2016","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2176\/nmc.ra.2014-0307","article-title":"Diagnosis of moyamoya disease: international standard and regional differences","volume":"55","author":"Fujimura","year":"2015","journal-title":"Neurol Med Chir."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.4081\/ni.2013.e2","article-title":"Reliability of the modified rankin scale applied by telephone","volume":"5","author":"Savio","year":"2013","journal-title":"Neurol Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3171\/2014.10.JNS132369","article-title":"Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China","volume":"122","author":"Liu","year":"2015","journal-title":"J Neurosurg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e678","DOI":"10.1212\/WNL.0000000000008901","article-title":"Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease","volume":"94","author":"Wang","year":"2020","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"B20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"GUSTO","year":"1993","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"B22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations. A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control Clin Trials"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.brat.2017.01.005","article-title":"A practical guide to propensity score analysis for applied clinical research","volume":"98","author":"Lee","year":"2017","journal-title":"Behav Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/iju.12603","article-title":"TriMatch comparison of the efficacy of FloSeal versus TachoSil versus no hemostatic agents for partial nephrectomy: results from a large multicenter dataset","volume":"22","author":"Antonelli","year":"2015","journal-title":"Int J Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00415-019-09277-1","article-title":"Clinical presentation of moyamoya angiopathy in Europeans: experiences from Germany with 200 patients","volume":"266","author":"Kraemer","year":"2019","journal-title":"J Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000007819","article-title":"Predictors of clinical or cerebral lesion progression in adult moyamoya angiopathy","volume":"93","author":"Herv\u00e9","year":"2019","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1161\/STROKEAHA.114.005624","article-title":"Long-term outcomes after combined revascularization surgery in adult moyamoya disease","volume":"45","author":"Cho","year":"2014","journal-title":"Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2019.12.JNS192938","article-title":"Late (5-20 years) outcomes after STA-MCA anastomosis and encephalo-duro-myo-arterio-pericranial synangiosis in patients with moyamoya disease","author":"Kuroda","year":"2020","journal-title":"J Neurosurg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10143-016-0734-7","article-title":"Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management","volume":"39","author":"Rashad","year":"2016","journal-title":"Neurosurg Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.wneu.2017.06.057","article-title":"Effect of aspirin in postoperative management of adult ischemic Moyamoya disease","volume":"105","author":"Zhao","year":"2017","journal-title":"World Neurosurg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.07.041","article-title":"Comparison of effects between clopidogrel and cilostazol on cerebral perfusion in nonsurgical adult patients with symptomatically ischemic moyamoya disease: subanalysis of a prospective cohort","volume":"27","author":"Chiba","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/neuros\/nyy234","article-title":"Two-year clinical, cerebral hemodynamic, and cognitive outcomes of adult patients undergoing medication alone for symptomatically ischemic moyamoya disease without cerebral misery perfusion: a prospective cohort study","volume":"84","author":"Miyoshi","year":"2019","journal-title":"Neurosurgery"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.608000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T05:52:21Z","timestamp":1610689941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.608000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":32,"alternative-id":["10.3389\/fneur.2020.608000"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.608000","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"article-number":"608000"}}